Objective:
To present phase 1/2a findings for the bispecific Tie2 agonist and VEGF inhibitor, tiespectus, in treatment-naïve eyes with wet age-related macular degeneration (AMD).
Approach:
- Clinical Trial Design: A phase 2 clinical trial involving 20 eyes with treatment-naïve AMD was conducted, investigating two doses of tiespectus (7 mg and 10 mg) with three initial monthly doses.
Key Findings:
- Tiespectus led to immediate and robust improvements in visual acuity, with an average gain of 5 letters at week 1 and over 7 letters by week 12.
- There were rapid and robust reductions in retinal thickness, with a decrease of over 215 µm by week 12.
- No ocular adverse events related to the drug were reported, and there were no serious ocular adverse events.
Limitations:
- The study involved a small sample size of only 20 eyes.
- Long-term efficacy and safety data are not yet available as the phase 3 clinical trial is ongoing.
Conclusion:
Further information will be available from the ongoing phase 3 clinical trial evaluating tiespectus.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.